SCHEMBL2484462

SCHEMBL2484462

Cc1cc(-c2ccccc2)c(C)c(OC(=O)c2ccccc2)c1OC(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 1/20 0.44
MAPT P10636 7/20 0.42
KMT2A Q03164 7/20 0.42
GAA P10253 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
NPBWR1 P48145 1/20 0.42
BACE1 P56817 1/20 0.42
LMNA P02545 4/20 0.42
MEN1 O00255 3/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
EGFR P00533 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.40
PTGS1 P23219 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
F2 P00734 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30035090 1.00 CA9 (0.44) CA9MAPTKMT2AGAAALDH1A1
SCHEMBL23136833 0.87 KMT2A (0.42) MAPTKMT2AGAAALDH1A1KDM4E
SCHEMBL2478940 0.84 PTGS1 (0.43) CA9MAPTKMT2AGAAALDH1A1
SCHEMBL2505244 0.84 KMT2A (0.46) MAPTKMT2AGAAALDH1A1KDM4E
SCHEMBL2482121 0.83 KMT2A (0.41) CA9MAPTKMT2AGAAALDH1A1
SCHEMBL2484012 0.83 MAPT (0.40) CA9MAPTKMT2AGAAALDH1A1
SCHEMBL23334735 0.83 KMT2A (0.44) MAPTKMT2AGAAALDH1A1KDM4E
SCHEMBL2485377 0.82 LMNA (0.41) CA9MAPTKMT2AGAAALDH1A1
SCHEMBL2476885 0.81 KMT2A (0.43) CA9MAPTKMT2AGAAALDH1A1
SCHEMBL23139309 0.81 KMT2A (0.43) MAPTKMT2AGAAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945896-B2 Catalyst composition and system having extended lifetime W.R. GRACE & CO.-CONN. (US) 2024-04-02 US disclosed
WO-2021055212-A1 CATALYST COMPOSITION AND SYSTEM HAVING EXTENDED LIFETIME W.R. GRACE & CO.-CONN. (US) 2021-03-25 WO disclosed
US-8604235-B2 Production of substituted phenylene aromatic diesters and compositions DOW GLOBAL TECHNOLOGIES LLC (US) 2013-12-10 US disclosed
EP-2376423-A1 PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS Dow Global Technologies LLC (US) 2011-10-19 EP disclosed
US-20100204506-A1 Production of Substituted Phenylene Aromatic Diesters and Compositions W. R. GRACE & CO.-CONN. 2010-08-12 US disclosed
WO-2010078519-A1 PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204506-A1 Production of Substituted Phenylene Aromatic Diesters and Compositions PAH, DDC, DDT CA9 1387/4885MAPT 2384/4885KMT2A 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.